3525-22-2

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-METHOXYPHENOXY)BENZOIC ACID 97 is used as an intermediate for the synthesis of various drugs. Its unique structure allows it to be a key component in the development of new pharmaceutical compounds, contributing to the advancement of medicinal chemistry.
Used in Dye Industry:
In the dye industry, 4-(4-METHOXYPHENOXY)BENZOIC ACID 97 is used as an intermediate for the synthesis of dyes. Its chemical properties make it suitable for the production of a wide range of dyes with different color characteristics and applications.
Used in Fragrance and Flavor Industry:
4-(4-METHOXYPHENOXY)BENZOIC ACID 97 is used as a raw material in the production of fragrances and flavors. Its aromatic nature lends itself to the creation of various scent profiles and taste profiles, enhancing the sensory experience of consumer products.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(4-METHOXYPHENOXY)BENZOIC ACID 97 is used as a versatile building block for the creation of a variety of organic compounds. Its reactivity and functional groups make it a valuable component in the synthesis of complex organic molecules.
Used in Specialty Chemicals Production:
4-(4-METHOXYPHENOXY)BENZOIC ACID 97 is also used as a raw material in the production of specialty chemicals. Its unique properties and reactivity contribute to the development of high-value specialty chemicals for various applications, including coatings, adhesives, and other industrial products.

InChI:InChI=1/C14H12O4/c1-17-11-6-8-13(9-7-11)18-12-4-2-10(3-5-12)14(15)16/h2-9H,1H3,(H,15,16)

Upstream product

• 120-47-8 Ethyl 4-hydroxybenzoate 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 109-72-8 n-butyllithium 
• 60-29-7 diethyl ether 
• 26002-36-8 1-iodo-4-(4-methoxyphenoxy)benzene 
• 3402-85-5 1-methoxy-4-(p-tolyloxy)benzene 
• 78725-47-0 4-(4-methoxyphenoxy)benzaldehyde 
• 591-51-5 phenyllithium 
• 456-22-4 4-Fluorobenzoic acid 
• 150-76-5 4-methoxy-phenol 
• 586-76-5 4-Bromobenzoic acid 
• 74-11-3 para-chlorobenzoic acid 
• 99-96-7 4-hydroxy-benzoic acid 
• 459-60-9 1-fluoro-4-methoxybenzene 

Downstream Products

• 500-76-5 4-(4-hydroxyphenoxy)benzoic acid 
• 38342-84-6 methyl 4-(4-methoxyphenoxy)benzoate 
• 80622-23-7 ethyl 4-(4-hydroxyphenoxy)benzoate 
• 5818-08-6 4-(4-methoxy-phenoxy)-benzoic acid hydrazide 
• 70151-68-7 4-(4-methoxy-phenoxy)-benzyl alcohol 
• 68548-50-5 4-(4-methoxy-phenoxy)-benzoyl chloride 
• 1436378-62-9 N-(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3-methylpiperazin-1-yl]-methyl}-2-methylpropyl-4-(4-methoxyphenoxy)benzamide 
• 1436378-63-0 N-(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3-methylpiperazin-1-yl]-methyl}-2-methylpropyl-4-(4-hydroxyphenoxy)benzamide 

Relevant academic research and scientific papers

Catalytic, Enantioselective α-Alkylation of Azlactones with Nonconjugated Alkenes by Directed Nucleopalladation

A palladium(II)-catalyzed enantioselective α-alkylation of azlactones with nonconjugated alkenes is described. The reaction employs a chiral BINOL-derived phosphoric acid as the source of stereoinduction, and a cleavable bidentate directing group appended to the alkene to control the regioselectivity and stabilize the nucleopalladated alkylpalladium(II) intermediate in the catalytic cycle. A wide range of azlactones were found to be compatible under the optimal reaction conditions to afford products bearing α,α-disubstituted α-amino-acid derivatives with high yields and high enantioselectivity.

Synthesis and antiproliferative activity of novel 4-substituted-phenoxy-benzamide derivatives

A series of novel 4-substituted-phenoxy-benzamide derivatives bearing an aryl cycloaliphatic amine moiety were synthesized and evaluated for antiproliferative activity against SW620, HT29 and MGC803 cancer cell lines in vitro. The pharmacological data demonstrated that the majority of target compounds exhibited moderate efficacy in HT29 and MGC803 cell lines. Compound 10c showed promising inhibition of hedgehog (Hh) signaling pathway in an Hh-related assay. In addition, the superposition pattern of 10c showed a good fit for a pharmacophoric model generated by Hh inhibitors and provided a basis for further structural optimization.

Evaluation of Novel N-(piperidine-4-yl)benzamide Derivatives as Potential Cell Cycle Inhibitors in HepG2 Cells

In this study, a series of novel N-(piperidine-4-yl)benzamide derivatives was designed, synthesized, and evaluated for antitumor activity. Some compounds were found to have potent antitumor activity. In particular, compound 47 showed the most potent biological activity against HepG2 cells, with an IC50 value of 0.25 μm. Western blot analysis demonstrated that compound 47 inhibited the expression of cyclin B1 and p-Rb and enhanced the expression of p21, p53, Rb, and phospho-adenosine monophosphate-activated protein kinase (p-AMPK). Further, cell cycle arrest was observed by flow cytometry (FCM). In summary, compound 47 was screened to have potential activity for the treatment of hepatocarcinoma via the induction of cell cycle arrest by a p53/p21-dependent pathway.

COMPOUNDS FOR TREATING VIRAL INFECTIONS

The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).

Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2- methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists

There is continuing interest in the discovery and development of new κ opioid receptor antagonists. We recently reported that N-substituted 3-methyl-4-(3-hydroxyphenyl)piperazines were a new class of opioid receptor antagonists. In this study, we report the syntheses of two piperazine JDTic-like analogues. Evaluation of the two compounds in an in vitro [35S] GTPγS binding assay showed that neither compound showed the high potency and κ opioid receptor selectivity of JDTic. A library of compounds using the core scaffold 21 was synthesized and tested for their ability to inhibit [35S]GTPγS binding stimulated by the selective κ opioid agonist U69,593. These studies led to N-[(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3- methylpiperazin-1-yl]methyl}-2-methylpropyl]-4-phenoxybenzamide (11a), a compound that showed good κ opioid receptor antagonist properties. An SAR study based on 11a provided 28 novel analogues. Evaluation of these 28 compounds in the [35S]GTPγS binding assay showed that several of the analogues were potent and selective κ opioid receptor antagonists.

Correlation between molecular dipole moment and centrosymmetry in some crystalline diphenyl ethers

The presence of a large molecular dipole moment in diphenyl ethers leads unequivocally to a centrosymmetric crystal structure. The Royal Society of Chemistry 2005.